AstraZeneca's Eneboparatide Frees 31% of Hypoparathyroidism Patients From Calcium and Vitamin D at Week 24 in CALYPSO Phase III
AstraZeneca's CALYPSO Phase III hit its composite primary endpoint with 31.1% of eneboparatide patients normalizing serum calcium and dropping supplements at week 24 versus 5.9% on placebo, with benefits sustained through a 52-week extension.
5 min read5 sources